Navigation Links
Dr Stephan Rietiker Joins BioCeramic Therapeutics
Date:1/9/2009

LONDON, January 9 /PRNewswire/ -- UK medical technology company BioCeramic Therapeutics Ltd is delighted to announce that Dr Stephan Rietiker has joined the company's Board of Directors. Dr Rietiker is widely recognized as a leading authority in BioCeramic Therapeutics' targeted sectors, particularly as former President and CEO of Centerpulse (formerly Sulzer Medical). His appointment follows the recent appointment of another renowned figure, Sir Richard Sykes, as Chairman of its Board of Directors and strengthens the company's management as it embarks on a new fundraising round to take its products through clinical trials.

"Given my professional background as a healthcare executive and in particular at Centerpulse, my primary focus is on getting involved in companies with leading edge technologies. As R&D activities in the biomaterials' arena are visibly gaining momentum, I'm delighted to be part of this fascinating venture. I fully believe in the technology and its future potential. Hence, I look forward to supporting the management team in efficiently reaching its strategic milestones and in creating significant value, both for patients and shareholders."

BCT is a pioneer in the exciting new field of regenerative medicine, bringing together some of the world's best materials scientists doctors, biologists and chemists in both private and public sectors. BCT is developing two families of implants designed to promote tissue regeneration. Initial applications are in orthopaedics and oral care, with plans to extend this to a wide range of other tissues important in human diseases.

Daniel Green, BCT's CEO, said: "I am delighted to welcome Stephan to the team. His input will be invaluable as we look to move our first BCT pipeline products through to clinic. Currently we are both exploring several licencing opportunities and embarking on a new fundraising round."

    Corporate Inquiries:
    Daniel Green, CEO
    BioCeramic Therapeutics
    Level One, Bessemer Building (RSM)
    Exhibition Road
    London SW7 2AZ,UK
    Tel +44(0)20-7594-1326
    email: djg@bioceramictherapeutics.com
    web:http://www.bioceramictherapeutics.com


'/>"/>
SOURCE BioCeramic Therapeutics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. John Stephen Osika, HIV/AIDS and Infectious Disease Expert, Joins Abt Associates
2. GEN Joins Charles Darwin 2009 Celebration
3. BioLife Solutions Joins Prestigious Biomedical Excellence for Safer Transfusion Collaborative
4. Maureen Mo Zilly Joins the Varian Medical Systems Government Affairs Team as Director, Federal Affairs
5. Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons
6. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
7. Pharos Innovations Joins Partnership to Fight Chronic Disease
8. Recognized Dermatology Expert Dr. Zoe Draelos Joins Histogen Scientific Advisory Board
9. Ethan Weiss, M.D., Joins Bionovos Scientific Advisory Board
10. Benjamin Custodio Joins Millennium Biotechnologies to Expand International Sales
11. Jerome Wilson Joins PRA Internationals Late Phase Service Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
Breaking Biology News(10 mins):